Spago’s phase I/IIa cancer study on track for 2025 completion

The independent Data Monitoring Committee (DMC) has approved the continuation of Spago Nanomedical’s phase I/IIa Tumorad-01 study at the highest current dose of 15 MBq/kg for its radiopharmaceutical candidate, 177Lu-SN201.

This follows a review of data from ten patients across three cohorts, representing eight different cancer types, including lung, throat, rectal, and liver cancer. The.